Graft Versus Host Disease – Epidemiology – Mature Markets

Clarivate Epidemiology’s coverage of graft versus host disease (GVHD) comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the United States, France, Germany, Italy, Spain, the United Kingdom, and Japan). We report both the diagnosed events and the diagnosed prevalence of GVHD for each country, as well as annualized counts projected to the national population.

Clarivate Epidemiology’s GVHD forecast will answer the following question:

• How will demographic trends, such as population aging and increasing life expectancy, affect the epidemiology of GVHD over the forecast period?

All forecast data are available on the Clarivate Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.

In total, Clarivate Epidemiology forecasts 10 GVHD patient populations, as follows:

• Diagnosed allogeneic HSCT events.
• Diagnosed acute GVHD events.
• Diagnosed chronic GVHD events.
• Diagnosed grade l acute GVHD events.
• Diagnosed grade ll acute GVHD events.
• Diagnosed grade lll acute GVHD events.
• Diagnosed grade lV acute GVHD events.
• Diagnosed limited chronic GVHD events.
• Diagnosed extensive chronic GVHD events.
• Diagnosed chronic GVHD prevalent cases.

Note: Coverage may vary by country.